This is exemplified by clinical trials of an anti-PD-1 antibody called nivolumab that resulted in rapid progression of adult T-cell leukemia-lymphomas [9] and T-cell lymphomas [10]. Here, PDCD1 is linked to T-cell non-Hodgkin lymphoma.